Phenotyping of chronic lung allograft dysfunction in the ScanCLAD study

ERJ Open Research 2026 Open access

Read full text
Authors: Jesper M. Magnusson, Peter M. Raivio, Inga Leuckfeld, Johan Svahn, Erik C. Holmberg, Thomas Kromann-Lund, Göran Dellgren
DOI: 10.1183/23120541.00084-2026
Cited by: 1
References: 9

Abstract

Extract Chronic lung allograft dysfunction (CLAD) remains the primary cause of long-term death or graft-failure after lung transplantation. The ScanCLAD trial demonstrated that tacrolimus-based immunosuppression significantly reduced CLAD incidence compared to ciclosporin (13% versus 39% at 3 years). However, CLAD phenotyping was not part of the original protocol. We report the first comprehensive phenotype analysis from a prospective randomized controlled trial in lung transplantation, employing a structured consensus process to classify CLAD phenotypes and assess their stability over time.

Fields of Study & Subjects

Transplantation: Methods and Outcomes Renal Transplantation Outcomes and Treatments Organ and Tissue Transplantation Research

Publication details

Journal / source
ERJ Open Research
Publisher
European Respiratory Society (ERS)
Volume
12
Issue
4
Pages
00084–2026
Publication date
20 February 2026
Language
EN